
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness - 2
The pinch at the pump continues on - 3
vote in favor of Your #1 kind of climate - 4
Tata Motors, BMW among automakers set to raise prices in India - 5
Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
South Carolina's measles outbreak reaches 434 cases
Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
Manual for 6 famous sorts of cheddar
Vietnam rethinks its flood strategy as climate change drives storms and devastation
NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
What is IDF's view on pontential long-term occupation of southern Lebanon?













